Clarivate Plc (CLVT)

FundamentalScore 3/5: Clarivate looks inexpensive on EV/EBITDA (~6.05x) and appears meaningfully cash-generative (FY2025 free-cash-flow yield ~23.86%), but leverage remains heavy (net debt/EBITDA ~4.42x) and EBIT interest coverage is still below 1x. SEC disclosures point to a potential balance-sheet improvement catalyst (planned $600M LS&H divestiture aimed at debt reduction), but closing/execution risk and ongoing GAAP losses keep the setup mixed.

Dominant catalyst is the pending close of the $600M Life Sciences & Healthcare divestiture to Altaris (announced confidence; its July coverage scored +0.5/+0.6), offset by a quiet near-term tape — the 14-day media aggregate is ~0.0 versus a +0.14 baseline, a determinate but essentially flat delta — and a $75M debt tender scored neutral. Retail velocity is indeterminate and a moderate red-flag cap applies for the court-docket-confirmed pending securities litigation.

CLVT is in a confirmed downtrend: price 1.87 sits below the SMA20 (2.01), SMA50 (2.05) and SMA200 (2.51) and below the EMA9 (1.93) and EMA21 (1.97) in a bearish moving-average stack. Momentum is negative — MACD line -0.04 with signal -0.03 and histogram -0.01 below zero — and RSI14 is 41.68, weak and under 50. ADX14 at 9.51 shows no trend strength either way, so the prevailing drift is weak but consistently down via lower highs (2.24 on 09-03, 2.05 on 09-08, 1.97 on 09-10, 1.93 on 09-16). Williams %R at -92.5 is deeply oversold, which at best argues for a reflex bounce, not a tradeable 1-15 day long. A pullback-to-support or oversold-reversal limit entry would also be blocked by the trend-alignment gate: price < SMA50 with macdLine < 0, and price < SMA200 (2.51) with SMA50 < SMA200 and no momentum reclaim (macdLine < 0, histogram < 0) — a knife-catch in a larger downtrend, not a dip within an uptrend. No bullish entry criteria are met; score 2 (weak bearish, bounce-only) is below the required 3.